Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index; 23 of the 25 sources its claims cite were checked for support.
Abstract
Background Patients who have had an acute coronary syndrome are at high risk for recurrent ischemic cardiovascular events. We sought to determine whether alirocumab, a human monoclonal antibody to proprotein convertase subtilisin–kexin type 9 (PCSK9), would improve cardiovascular outcomes after an acute coronary syndrome in patients receiving high‐intensity statin therapy. Methods We conducted a multicenter, randomized, double‐blind, placebo‐controlled trial involving 18,924 patients who had an acute coronary syndrome 1 to 12 months earlier, had a low‐density lipoprotein (LDL) cholesterol level of at least 70 mg per deciliter (1.8 mmol per liter), a non‐high‐density lipoprotein cholesterol level of at least 100 mg per deciliter (2.6 mmol per liter), or an apolipoprotein B level of at least 80 mg per deciliter, and were receiving statin therapy at a high‐intensity dose or at the maximum tolerated dose. Patients were randomly assigned to receive alirocumab subcutaneously at a dose of 75 mg (9462 patients) or matching placebo (9462 patients) every 2 weeks. The dose of alirocumab was adjusted under blinded conditions to target an LDL cholesterol level of 25 to 50 mg per deciliter (0.6 to 1.3 mmol per liter). The primary end point was a composite of death from coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization. Results The median duration of follow‐up was 2.8 years. A composite primary end‐point e…
Overview
CoChat Summary
TL;DR
In patients with a recent acute coronary syndrome receiving high-intensity or maximum-tolerated statin therapy, alirocumab reduced the risk of recurrent ischemic cardiovascular events compared with placebo. The benefit was driven mainly by the composite primary end point, with similar adverse-event rates except for more local injection-site reactions.
Key findings
- The primary composite end point occurred in 903 patients (9.5%) in the alirocumab group vs. 1052 patients (11.1%) in the placebo group (hazard ratio, 0.85; 95% CI, 0.78 to 0.93; P<0.001); the 4-year Kaplan-Meier estimate was 12.5% vs. 14.5%, and 49 patients would need treatment for 4 years to prevent one primary event.
- Death from any cause occurred in 334 patients (3.5%) in the alirocumab group vs. 392 patients (4.1%) in the placebo group (hazard ratio, 0.85; 95% CI, 0.73 to 0.98).
- Absolute benefit was greater among patients with baseline LDL cholesterol ≥100 mg/dL; in that nonprespecified subgroup, 16 patients (95% CI, 11 to 34) would need treatment for 4 years to prevent one primary event (P<0.001 for interaction).
- Adverse events were similar between groups except local injection-site reactions, which occurred in 3.8% of alirocumab patients vs. 2.1% of placebo patients (P<0.001).
Methods
- Multicenter, randomized, double-blind, placebo-controlled trial enrolling 18,924 patients who had an acute coronary syndrome 1 to 12 months earlier and elevated atherogenic lipid levels despite high-intensity or maximum-tolerated statin therapy.
- Patients were randomly assigned 1:1 to subcutaneous alirocumab 75 mg every 2 weeks (9462 patients) or matching placebo (9462 patients), with blinded dose adjustment targeting LDL cholesterol 25 to 50 mg/dL.
- The primary end point was a composite of death from coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization; median follow-up was 2.8 years, with intention-to-treat Cox proportional-hazards analysis stratified by geographic region.
Limitations
- The paper states that a limitation of all three PCSK9 antibody trials, including this one, is infrequent use of ezetimibe because its cardiovascular efficacy was established after most patients had already been enrolled.
- The paper states that whether safety and efficacy were influenced by the blinded dose-adjustment strategy is unknown, and that neither this trial nor FOURIER can fully predict longer-term safety of PCSK9 monoclonal antibody treatment.
- Evident from the text: median follow-up was 2.8 years, limiting assessment of longer-term outcomes; the baseline LDL cholesterol ≥100 mg/dL subgroup finding was from a nonprespecified analysis.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
15 Valid · 1 Not valid · 3 Not checked · 54 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“These findings have led to the development of monoclonal antibodies to PCSK9 that produce substantial reductions in LDL cholesterol when administered alone or with a statin. 8-12”
What the sources say
- Supportedcites [8] 8. Stein EA, Mellis S, Yancopoulos GD, et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med 2012; 366: 1108-18. source
The Discussion (page not supplied) states that REGN727 lowered LDL cholesterol both alone and in subjects already receiving atorvastatin. The Lipid and Lipoprotein Response section reports substantial reductions in the atorvastatin-treated groups. (LLM, conf=0.93)
- Could not verifycites [9] 9. Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1489-99. sourceExperimental — accuracy not yet measured
The supplied copy contains repository metadata and a PDF listing, but no passage reporting LDL-cholesterol outcomes (Abstract listing). Searches for PCSK9 antibodies, alirocumab, LDL reduction, and use with or without a statin returned no matching passages. The claim therefore cannot be checked against our copy. (LLM, conf=0.78)
- Supportedcites [10] 10. Blom DJ, Hala T, Bolognese M, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med 2014; 370: 1809-19. source
The Efficacy End Points section reports substantial LDL-cholesterol reductions with the PCSK9 monoclonal antibody evolocumab both in the diet-alone group and in groups receiving atorvastatin. The paper also describes earlier trials of PCSK9 inhibitors that significantly reduced LDL cholesterol. (LLM, conf=0.92)
- Supportedcites [11] 11. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017; 376: 1713-22. source
The Introduction (p. 1714) says PCSK9 monoclonal antibodies effectively lower LDL cholesterol and that evolocumab reduces it by approximately 60%. Its cited studies include both an anti-PCSK9 monotherapy trial and a trial adding evolocumab to statin therapy (References); the Discussion also reports a 59% reduction with statin therapy. (LLM, conf=0.88)
- Supportedcites [12] 12. Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1500-9. source
The paper describes PCSK9 monoclonal antibodies as very effective at lowering LDL cholesterol. Its End Points table includes evolocumab trials with no background lipid therapy and trials with statins; the Lipid Changes section reports a 61% LDL-cholesterol reduction with evolocumab versus standard therapy at 12 weeks. The reported reduction is pooled, not a separate estimate for each treatment setting. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Patients who have had an acute coronary syndrome are at high risk for recurrent ischemic cardiovascular events.”
What the sources say
- Partly supportedcites [1] 1. Fox KA, Goodman SG, Klein W, et al. Management of acute coronary syndromes - variations in practice and outcome; findings from the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2002; 23: 1177-89. sourceExperimental — accuracy not yet measured
The Results section (p. 1181) reports in-hospital reinfarction after acute coronary syndrome, supporting a risk of recurrent events during admission. The paper says six-month outcomes were collected (Data collection), but it does not report those results here, so it does not establish a high risk of recurrent events after discharge. (LLM, conf=0.80)
- Partly supportedcites [2] 2. Jernberg T, Hasvold P, Henriksson M, Hjelm H, Thuresson M, Janzon M. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a longterm perspective. Eur Heart J 2015; 36: 1163-70. sourceExperimental — accuracy not yet measured
The Results report an 18.3% one-year risk of MI, stroke, or cardiovascular death after an index MI, and the Discussion says risk remained high in subsequent years. This supports the claim for patients after MI, but the study does not establish the same risk for all patients after acute coronary syndrome, a broader group. (LLM, conf=0.84)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Similarly, a recent meta-analysis showed that intensive lowering of LDL cholesterol (primarily with the use of statins) resulted in a mortality benefit that was observed only among patients with a baseline LDL cholesterol level of 100 mg or more per deciliter. 20”
What the sources say
- Supportedcites [20] 20. Navarese EP, Robinson JG, Kowalewski M, et al. Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: a systematic review and meta-analysis. JAMA 2018; 319: 1566-79. source
The All-Cause Mortality and Cardiovascular Mortality sections report mortality risk reductions with more intensive LDL-C lowering only in trials with baseline LDL-C levels of at least 100 mg/dL. The Study Selection and Patient Population section reports that 26 of the 34 trials used statin monotherapy, supporting “primarily with statins.” The threshold describes trial-level baseline LDL-C, rather than a demonstrated cutoff for individual patients. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“A limitation of all three trials is the infrequent use of ezetimibe, for which cardiovascular efficacy was established 5 after most of the patients had already been enrolled and the trials were well under way.”
What the sources say
- Supportedcites [5] 5. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015; 372: 2387-97. source
The citation is attached to the assertion that ezetimibe’s cardiovascular efficacy was established. The Conclusions report improved cardiovascular outcomes when ezetimibe was added to statin therapy, and the Efficacy End Points section reports significantly fewer cardiovascular events. The timing relative to the citing authors’ three trials is their own framing, not a finding attributed to this source. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The current trial and the FOURIER trial showed similar improvements in composite cardiovascular outcomes with PCSK9 inhibition among patients who had a baseline LDL cholesterol level of 70 mg or more per deciliter and whose average baseline LDL cholesterol level was approximately 90 mg per deciliter. 10”
What the sources say
- Partly supportedcites [10] 10. Blom DJ, Hala T, Bolognese M, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med 2014; 370: 1809-19. sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 1 unverifiable. Expand the claim to see per-atom verdicts.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
24 more claims · 3 with their cited sources checked
Create a free account to see all 73 claims and every source verdict.
- Probably not a substantial claim. 20
- It may state two separate claims as one. 27
- The quote only partly states this claim. 4
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the cumulative data from the FOURIER and ODYSSEY OUTCOMES trials suggest that PCSK9 inhibitors effectively lower LDL-C and cardiovascular risk in individuals with CAD regardless of diabetes mellitus status.”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [126]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Two RCTs have reported a beneficial effect on clinical endpoints in ASCVD patients without FH [119,120].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [119]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The mAb PCSK9 inhibitors evolocumab and alirocumab lower LDLC levels by ∼60% and, when added to statin therapy, decrease the risk of major vascular events [119].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [119]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the FOURIER trial, which included 27 564 patients with atherosclerotic CV disease, the addition of evolocumab to statin therapy (69% high-intensity therapy) resulted in a 15% relative risk reduction of the composite primary endpoint throughout a 2.2 year follow-up.”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [119]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, the best evidence to support lower LDL cholesterol targets in people with diabetes and established cardiovascular disease derives from multiple large randomized trials investigating the benefi ts of adding nonstatin agents to statin therapy.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [110]
Experimental — accuracy not yet measured
32 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Patients, Trial Regimen, and Follow-up
“In China, 613 patients underwent randomization from May 2016 through February 2017.”
§ Statistical Analysis
“In China, 614 patients underwent randomization after random assignment of the main trial cohort had been completed”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“| Missing data | 19 (<0.1) | 12 (<0.1) |”
Reported 0.1 · recomputed 0.200803
Citations
Cites
Ibanez, B., James, S., Agewall, S., Antunes, M. J., Bucciarelli-Ducci, C., Bueno, H., Caforio, A. L. P., Crea, F., Goudevenos, J. A., Halvorsen, S., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx393 · Cited by 9,728
Self-citationRoffi, M., Patrono, C., Collet, J.-P., Mueller, C., Valgimigli, M., Andreotti, F., Bax, J. J., Borger, M. A., Brotons, C., Chew, D. P., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv320 · Cited by 8,261
Self-citationEvolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Self-citation2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
Amsterdam, E. A., Wenger, N. K., Brindis, R. G., Casey, D. E., Ganiats, T. G., Holmes, D. R., Jaffe, A. S., Jneid, H., Kelly, R. F., Kontos, M. C., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.09.017 · Cited by 3,595
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
Abifadel, M., Varret, M., Rabès, J.-P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., et al. (2003) · Nature Genetics · doi:10.1038/ng1161 · Cited by 2,985
2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction
O'Gara, P. T., Kushner, F. G., Ascheim, D. D., Casey, D. E., Chung, M. K., de Lemos, J. A., Ettinger, S. M., Fang, J. C., Fesmire, F. M., Franklin, B. A., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.11.019 · Cited by 2,625
Schwartz, G. G. (2001) · JAMA · doi:10.1001/jama.285.13.1711 · Cited by 2,499
Self-citation
Cited by
Items 1,201–1,300 of 3,636
PCSK9 in Liver Cancers at the Crossroads between Lipid Metabolism and Immunity
Alannan, M., Seidah, N. G., & Merched, A. J. (2022) · Cells · doi:10.3390/cells11244132 · Cited by 22
“Alirocumab (Praluent) mAb FDA-approved for treating hypercholesterolemia +/− Statins [119,122,123]”
BackgroundImpact of lipid lowering on coronary atherosclerosis moving from the lumen to the artery wall
Giovanni, G. D., Kataoka, Y., Bubb, K. J., Nelson, A. J., & Nicholls, S. J. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.01.017 · Cited by 16
PCSK9 Inhibition in Atherosclerotic Cardiovascular Disease
Delialis, D., Dimopoulou, M., Papaioannou, M., Kotsira, G., Maneta, E., Mavraganis, G., Loutos, C., Georgiopoulos, G. A., & Stamatelopoulos, K. S. (2023) · Current Pharmaceutical Design · doi:10.2174/1381612829666230412105238 · Cited by 14
Appropriateness of Dyslipidemia Management Strategies in Post-Acute Coronary Syndrome: A 2023 Update
Lucà, F., Oliva, F. G., Rao, C. M., Abrignani, M. G., Amico, A. F., Fusco, S. A. D., Caretta, G., Matteo, I. D., Nora, C. D., Pilleri, A., et al. (2023) · Metabolites · doi:10.3390/metabo13080916 · Cited by 20
Cordero, A., Olmo, R. F., Badimón, L., Santos‐Gallego, C. G., Castellano, J. M., Fácila, L., Rodríguez‐Mañero, M., Bonanad, C., Vilahur, G., Escribano, D., et al. (2023) · Journal of clinical lipidology · doi:10.1016/j.jacl.2023.08.006 · Cited by 18
Miles, J. A., Scotti, A., Castagna, F., Kuno, T., Leone, P. P., Coisne, A., Ludwig, S., Lavie, C. J., Joshi, P. H., Latib, A., et al. (2023) · Circulation · doi:10.1161/circulationaha.123.064566 · Cited by 15
Atia, A., Aboeldahab, H. A., Wageeh, A., Elneny, M., Elmallahy, M., Elawfi, B., Aboelkhier, M. M., Elrosasy, A., Abdelwahab, M. M., Sayed, S., et al. (2024) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-023-00621-5 · Cited by 17
“We assess the risk of bias of 11 RCTs included using ROB2, of which seven studies [26–32] had an overall low risk of bias, while the other studies showed an overall unclear bias due to the following reasons: (1) their method of randomizing patients, nearly 20%, and (2) missing outcomes reporting…”
MethodColchicine for the Prevention of Cardiovascular Disease: Potential Global Implementation
Zhang, R. S., Weber, B., Garaygordobil, D. A., & Garshick, M. S. (2024) · Current Cardiology Reports · doi:10.1007/s11886-024-02049-y · Cited by 20
Strategies for chronic coronary disease: A brief guide for clinicians
Krittanawong, C., Khawaja, M., Virk, H. U. H., Escobar, J., Khalid, U., Birnbaum, Y., Lavie, C. J., Sharma, S. K., Jneid, H. M., Rao, S. V., et al. (2024) · npj Cardiovascular Health · doi:10.1038/s44325-024-00006-w · Cited by 21
Katsuki, S., Jha, P. K., Aïkawa, E., & Aikawa, M. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1431398 · Cited by 18
“Pivotal studies such as the FOURIER trial (10) and ODYSSEY OUTCOMES trial (11) have demonstrated the ef fi cacy of PCSK9 antibodies in reducing cardiovascular events in primary and secondary prevention, respectively, representing recent advancements in PCSK9-targeted intensive lipid lowering…”
BackgroundThe Cardioprotective Effects of Nutritional Ketosis: Mechanisms and Clinical Implications
Venturini, C., Mancinelli, L., Matacchione, G., Olivieri, F., & Antonicelli, R. (2024) · Nutrients · doi:10.3390/nu16234204 · Cited by 16
LP(a): The new marker of high cardiovascular risk
Averna, M. R., & Cefalu, A. B. (2024) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2024.103845 · Cited by 17
Update of therapeutic planning tables oriented towards obtaining therapeutic objectives
Masana, L., & Plana, N. (2019) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2019.10.001 · Cited by 15
Kazi, D. S., & Virani, S. S. (2019) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2019.10.006 · Cited by 16
Jia, X., Rifai, M. A., Gluckman, T. J., Birnbaum, Y., & Virani, S. S. (2019) · Current Atherosclerosis Reports · doi:10.1007/s11883-019-0813-7 · Cited by 14
Identifying Markers of Cardiovascular Event-Free Survival in Familial Hypercholesterolemia
Khoury, É., Brisson, D., Roy, N., Tremblay, G., & Gaudet, D. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm10010064 · Cited by 15
“In fact, evidence showing the reduction in CVD-associated mortality and morbidity in patients using lipid-lowering medications was first described by the Scandinavian Simvastatin Survival Study (4S) trial with statins [38], and recently demonstrated by the CV outcome studies with the FOURIER (evolocumab) [39] and ODYS…”
BackgroundForte, F., Calcaterra, I. L., Lupoli, R., Orsini, R. C., Chiurazzi, M., Tripaldella, M., Iannuzzo, G., & Minno, M. N. D. D. (2020) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaa029 · Cited by 16
Zhou, R., Stouffer, G. A., & Smith, S. C. (2021) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/10742484211023632 · Cited by 15
“1%).(30) The prespecified post hoc analysis by baseline LDL-C level showed reduced CHD or cardiovascular death and all-cause mortality but only in patients with baseline LDL-C level of 100 mg/dl or above.”
Waldmann, E., Li-ya, W., Busygina, K., Altenhofer, J., Henze, K., Folwaczny, A., & Parhofer, K. G. (2022) · PLoS ONE · doi:10.1371/journal.pone.0265838 · Cited by 15
Vekić, J., Zeljković, A., Stefanović, A., Bogavac‐Stanojević, N., Ilias, Ι., Silva‐Nunes, J., Stoian, A. P., Janež, A., & Rizzo, M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14040825 · Cited by 17
“Convincing data from the FOURIER [23] and ODYSSEY OUTCOMES [24] trials demonstrated substantial LDL-C level reduction by 50% with evolocumab and alirocumab, respectively.”
MethodEffect of PCSK9 Inhibitors on Hemostasis in Patients with Isolated Hypercholesterolemia
Basiak, M., Hachuła, M., Kosowski, M., & Okopień, B. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11092542 · Cited by 14
“They found that high efficacy in reducing cardiovascular risk does not appear to be entirely dependent on lipoproteinlowering effects [17,18].”
BackgroundCarbohydrate and Lipid Metabolism Research Unit, F. O. H. S., Raal, F., Ableson, M., Vergelegen Mediclinic, S. W., Blignaut, S., Paarl Research Centre, P., Burgess, L., Tread Research, C. U., Coetzer, S., Accelerated Enrollment Solutions, H. C. R. C., et al. (2022) · South African Medical Journal · doi:10.7196/samj.2022.v112i6.16253 · Cited by 14
“The fully humanised monoclonal antibodies (mAbs) to protein convertase subtilisin/kexin type 9 (PCSK9), alirocumab and evolocumab, are highly effective in lowering LDL-C by 50 - 60% in patients with heterozygous familial hypercholesterolaemia (HeFH) and/or established ASCVD.[12-15] More recently, inclisiran, a small-i…”
BackgroundInfluentialChiang, C., Schwartz, G. G., Elbez, Y., Szarek, M. J., Bhatt, D. L., Bittner, V., Díaz, R., Ērglis, A., Goodman, S. G., Hagström, E., et al. (2022) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2022.05.021 · Cited by 17
“Alirocumab was associated with consistent relative risk reductions in both patients with and without previous MI, with numerically greater absolute bene fi t in patients with previous MI.”
InfluentialSelf-citationGaine, S. P., Quispe, R., Patel, J., & Michos, E. D. (2022) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-022-00694-y · Cited by 15
Alanaeme, C. J., Bittner, V., Brown, T. M., Colantonio, L. D., Dhalwani, N. N., Jones, J., Kalich, B. A., Exter, J., Jackson, E. A., Levitan, E. B., et al. (2022) · American Heart Journal Plus Cardiology Research and Practice · doi:10.1016/j.ahjo.2022.100201 · Cited by 18
“The relative reduction in ASCVD risk with lipid-lowering medications is proportional to the degree to which LDL-C is lowered [22 – 24].”
BackgroundSelf-citationUptake of non-statin lipid-lowering therapies for secondary prevention in community practice
Bradley, C., Kolkailah, A. A., Shah, N. P., Page, C. B., Peterson, E. D., & Návar, A. M. (2023) · Journal of clinical lipidology · doi:10.1016/j.jacl.2023.03.006 · Cited by 15
Lee, G., Durante, Á., Baker, E. J., Vellone, E., Caggianelli, G., Dellafiore, F., Khan, M., & Khatib, R. (2023) · Journal of Advanced Nursing · doi:10.1111/jan.15739 · Cited by 15
Banerjee, S., Luo, P., Reda, D. J., Latif, F., Hastings, J. L., Armstrong, E. J., Bagai, J., Abu-Fadel, M. S., Baskar, A., Kamath, P., et al. (2020) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.119.008933 · Cited by 14
More- Versus Less-Intensive Lipid-Lowering Therapy: Systematic Review and Meta-Analysis
Toyota, T., Morimoto, T., Yamashita, Y., Shiomi, H., Kato, T., Makiyama, T., Nakagawa, Y., Saito, N., Shizuta, S., Ono, K., et al. (2019) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.118.005460 · Cited by 16
Have the Major Cardiovascular Outcomes Trials Impacted Payer Approval Rates for PCSK9 Inhibitors?
Návar, A. M., Mulder, H. S., WOJDYLA, D. M., & Peterson, E. D. (2020) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.119.006019 · Cited by 14
Hovland, A., Retterstøl, K., Mollnes, T. E., Halvorsen, B. L., Aukrust, P., & Lappegård, K. T. (2020) · Scandinavian Cardiovascular Journal · doi:10.1080/14017431.2020.1775878 · Cited by 16
“This leads to a reduction in cardiovascular clinical endpoints [34,35].”
BackgroundSolomon, A., Stanwix, A. E., Castañeda, S., Llorca, J., González‐Juanatey, C., Hodkinson, B., Benitha, R., Ally, M. M. T. M., Maharaj, A. B., van Duuren, E., et al. (2020) · BMC Rheumatology · doi:10.1186/s41927-020-00139-2 · Cited by 17
Nambi, V., & Agha, A. M. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.01.008 · Cited by 18
Pro-Inflammatory Implications of 2-Hydroxypropyl-β-cyclodextrin Treatment
Houben, T., Yadati, T., de Kruijf, R. F., Gijbels, M. J., Luiken, J. J. F. P., van Zandvoort, M. A. M. J., Kapsokalyvas, D., Lütjohann, D., Westerterp, M., Plat, J., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.716357 · Cited by 18
“A straightforward and successfully applied approach to reduce cholesterol levels is via pharmacological approaches, which include the use of statins (11), fibrates (12) and more recently antibodies targeting proprotein convertase subtilisinkexin type 9 (PCSK9) (13).”
BackgroundCondello, F., Sturla, M., Reimers, B., Liccardo, G., Stefanini, G. G., Condorelli, G., & Ferrante, G. (2021) · European Cardiology Review · doi:10.15420/ecr.2021.31 · Cited by 16
Ruscica, M., Watts, G. F., & Sirtori, C. R. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487319833504 · Cited by 14
Brinton, E. A. (2021) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.121.316893 · Cited by 16
Cardiovascular Risk Assessment and Lipid-Lowering Therapy Recommendations in Primary Prevention
Komnianou, A., Kyriakoulis, K. G., Menti, A., Dimakakos, E. P., Stergiou, G. S., & Κόλλιας, Α. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14072220 · Cited by 17
“Their efficacy in CVD prevention has been confirmed in the secondary prevention setting [45,46].”
Drug Discovery for Coronary Artery Disease
Wan, Q., Qian, S., Yonghu, H., Zhang, Y., Peng, Z., Li, Q., Shu, B., Zhu, L., & Wang, M. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-2517-9_8 · Cited by 13
Belkadi, A., Thareja, G., Abbaszadeh, F., Badii, R., Fauman, E. B., Albagha, O., & Suhre, K. (2022) · Cell Genomics · doi:10.1016/j.xgen.2022.100218 · Cited by 13
Mechanisms of unusual response to lipid-lowering therapy: PCSK9 inhibition
Ouyang, M., Li, C., Hu, D., Peng, D., & Yu, B. (2022) · Clinica Chimica Acta · doi:10.1016/j.cca.2022.11.018 · Cited by 13
Li, Y., Yang, M., Chen, X., Zhang, R., Li, J., Zhang, X., Zuo, P., & Ma, G. (2022) · Journal of Interventional Cardiology · doi:10.1155/2022/4797529 · Cited by 14
Tada, H., Nomura, A., Nohara, A., Usui, S., Sakata, K., Hayashi, K., Fujino, N., Takamura, M., & Kawashiri, M. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.03.005 · Cited by 15
Babadagli, H. E., Barry, A. R., Thanassoulis, G., & Pearson, G. J. (2023) · Canadian Pharmacists Journal / Revue des Pharmaciens du Canada · doi:10.1177/17151635231164989 · Cited by 12
“Since the 2016 CCS dyslipidemia guidelines, 2 new trials (FOURIER and ODYSSEY OUTCOMES) with PCSK9 inhibitors have been published (refer to Table 3 for details).(18,19) Both evolocumab and alirocumab lower LDL-C by about 60% when used in addition to statin therapy and are approved for add-on therapy to statins in seco…”
BackgroundMethodImpact of Lipoprotein (a) on Long-Term Outcomes in Patients With Acute Myocardial Infarction
Dai, K., Shiode, N., Yoshii, K., Kimura, Y., Matsuo, K., Jyuri, Y., Tomomori, S., Higaki, T., Oi, K., Kawase, T., et al. (2023) · Circulation Journal · doi:10.1253/circj.cj-23-0221 · Cited by 16
Sagris, D., Ntaios, G., & Milionis, H. J. (2023) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2022-329149 · Cited by 13
“Currently, two monoclonal antibodies against PCSK9, alirocumab and evolocumab, significantly reduce the levels of LDL-C and simultaneously the incidence of new CV events and ischaemic stroke, 28 29 while their effect is also consistent among patients with previous cerebrovascular event.”
BackgroundTang, L., Chen, H., Hu, X., Fang, Z., Liao, X., Zhou, X., Yang, H., Tu, T., Zhu, Z., Zhou, S., et al. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.123.029397 · Cited by 13
PCSK9 activation promotes early atherosclerosis in a vascular microphysiological system
Lee, J. H., Shores, K. L., Breithaupt, J. J., Lee, C. S., Fodera, D. M., Kwon, J. B., Ettyreddy, A. R., Myers, K. M., Evison, B. J., Suchowerska, A. K., et al. (2023) · APL Bioengineering · doi:10.1063/5.0167440 · Cited by 13
Ferlini, M., Munafò, A. R., Varbella, F., Delnevo, F., Solli, M., Trabattoni, D., Piccaluga, E., Cardile, A., Canova, P. A., Rossini, R., et al. (2023) · International Journal of Cardiology · doi:10.1016/j.ijcard.2023.131659 · Cited by 16
Role of PCSK9 inhibitors in the management of dyslipidaemia
Nair, T. (2024) · Indian Heart Journal · doi:10.1016/j.ihj.2023.12.011 · Cited by 18
Iqbal, S., Sabbour, H. M., Ashraf, T., Santos, R. D., & Buckley, A. (2024) · Clinical Therapeutics · doi:10.1016/j.clinthera.2023.12.003 · Cited by 13
Efficacy and safety of PCSK9 inhibitors for stroke prevention: Systematic review and meta-analysis
Moustafa, B., Oparowski, D., Testai, S., Guman, I., & Trifan, G. (2024) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2024.107633 · Cited by 18
Verghese, D., Hamal, S. A., Ghanem, A. M., Kinninger, A., Javier, D., Ichikawa, K., Benzing, T., Krishnan, S., Kianoush, S., Hamidi, H., et al. (2024) · American Heart Journal · doi:10.1016/j.ahj.2024.07.005 · Cited by 15
Emerging Therapeutic Targets for Acute Coronary Syndromes: Novel Advancements and Future Directions
Mitsis, A., Myrianthefs, M. M., Sokratous, S., Karmioti, G., Kyriakou, M., Drakomathioulakis, M., Tzikas, S., Kadoglou, N. P. E., Karagiannidis, E., Nasoufidou, A., et al. (2024) · Biomedicines · doi:10.3390/biomedicines12081670 · Cited by 18
Recent progress in gene therapy for familial hypercholesterolemia treatment
Luo, Y., Hou, Y., Zhao, W., & Yang, B. (2024) · iScience · doi:10.1016/j.isci.2024.110641 · Cited by 15
Sheth, S., Banach, M., & Toth, P. P. (2024) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2024.2398444 · Cited by 16
“ODYSSEY-OUTCOMES assessed the efficacy of the PCSK9 inhibitor (PCSK9i) alirocumab among patients who had a recent acute coronary syndrome (ACS) with high atherogenic lipoprotein levels and high-intensity or maximally tolerated statin dosage [24].”
Choo, E. H., Moon, D., Choi, I. J., Lim, S., Lee, J., Kang, D., Hwang, B., Kim, C. J., Lee, J. M., Yoo, K., et al. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02498-3 · Cited by 15
“Risk reduction achieved through LDL-C lowering, rather than statin intensity alone, is now supported by multiple studies, including earlier trials and meta-analyses, as well as recent randomized controlled trials with non-statin therapies [21–24].”
ResultZeng, W., Zhou, F., Zhao, H., Wang, Y., Chen, J., Lu, J., Zheng, D., Kuang, J., Yuan, D., Zhou, J., et al. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.035651 · Cited by 12
PCSK9 inhibition 2018: riding a new wave of coronary prevention
Ward, N. C., Page, M. M., & Watts, G. F. (2019) · Clinical Science · doi:10.1042/cs20171300 · Cited by 14
Cordero, A., Fácila, L., Rodríguez‐Mañero, M., et al. (2019) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2019.03.008 · Cited by 13
Medical Management for Secondary Stroke Prevention
Kim, A. S. (2020) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000000849 · Cited by 15
Barter, P. J., Yamashita, S., Laufs, U., Ruiz, Á. J., Sy, R. G., Fang, M. D. G., Folco, E., Libby, P., Matsuzawa, Y., & Santos, R. D. (2020) · Lipids in Health and Disease · doi:10.1186/s12944-020-01265-z · Cited by 15
“While there is compelling evidence that a very low level of LDL-C may increase the risk of haemorrhagic stroke [18], especially in Asians [19], it is pertinent that there was no increase in risk at very low LDL-C levels attained by adding ezetimibe [3] or a PCSK9 inhibitor [4, 5] to background statin therapy in major…”
BackgroundD’Erasmo, L., Commodari, D., Costanzo, A. D., Minicocci, I., Polito, L., Ceci, F., Montali, A., Maranghi, M., & Arca, M. (2020) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2020.06.028 · Cited by 15
Prevalence, treatment, and control of severe hyperlipidemia
Gold, M. E., Nanna, M. G., Doerfler, S. M., Schibler, T., WOJDYLA, D. M., Peterson, E. D., & Návar, A. M. (2020) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2020.100079 · Cited by 19
Ramos, P. M., Giraldo, Y. G., Chiva, V. Á., Arroyo, D., Sango, C., Moncho, F., Ocaña, J., Reque, J., Sánchez-Álvarez, E., Górriz, J. L., et al. (2021) · Metabolites · doi:10.3390/metabo11110760 · Cited by 16
“The inhibition of PCSK9 leads to substantial reductions in LDL-C levels and improved cardiovascular event-free survival, as revealed by the results from the pivotal FOURIER and ODYSSEY OUTCOMES randomized clinical trials (RCT) [8,9].”
InfluentialIannuzzo, G., Buonaiuto, A., Calcaterra, I. L., Gentile, M., Forte, F., Tripaldella, M., Taranto, M. D. D., Giacobbe, C., Fortunato, G., Rubba, P., et al. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.10.025 · Cited by 15
Pharmacogenomic Study of Statin-Associated Muscle Symptoms in the ODYSSEY OUTCOMES Trial
Murphy, W. A., Lin, N., Damask, A., Schwartz, G. G., Steg, P. G., Szarek, M. J., Banerjee, P., Fazio, S., Manvelian, G. Z., Pordy, R. C., et al. (2022) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.121.003503 · Cited by 16
Self-citationPCSK9 Knockdown Can Improve Myocardial Ischemia/Reperfusion Injury by Inhibiting Autophagy
Huang, G., Lu, X., Duan, Z., et al. (2022) · Cardiovascular Toxicology · doi:10.1007/s12012-022-09771-5 · Cited by 13
“It is well known that myocardial infarct size is linked to reperfusion opening time, and mortality may be further lowered if myocardial infarct size can be significantly reduced [16, 17].”
BackgroundShah, N. P., Page, C. B., Green, C. L., Gao, M., Cavalier, J. S., McGarrah, R. W., DeWald, T. A., Sangvai, D. G., Patel, M. R., & Pagidipati, N. J. (2022) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2022.10.033 · Cited by 13
National Institute for Health and Care Excellence guidelines for lipid management
Cegla, J. (2022) · Heart · doi:10.1136/heartjnl-2022-321414 · Cited by 16
Lan, N. S. R., Bell, D. A., Watts, G. F., & Fegan, P. G. (2022) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000790 · Cited by 13
Inclisiran: present and future perspectives of a new effective LDL cholesterol-lowering agent
Giordano, S. A., Polimeni, A., Esposito, G., Indolfi, C., & Spaccarotella, C. (2023) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000877 · Cited by 13
Seijas-Amigo, J., Mauriz-Montero, M. J., Suarez-Artime, P., Gayoso-Rey, M., Estany-Gestal, A., Casas-Martínez, A., González-Freire, L., Rodriguez-Vazquez, A., Pérez-Rodriguez, N., Villaverde-Piñeiro, L., et al. (2023) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-023-00604-6 · Cited by 13
“of PCSK9i that demonstrated in randomized clinical trials the ability to reduce the LDL-C levels by about 60% [9, 10].”
BackgroundResultInfluentialClinician's Guide to the Updated ABCs of Cardiovascular Disease Prevention: A Review Part 2
Arps, K. E., Pallazola, V. A., Cardoso, R. N., Meyer, J., Jones, R., Latina, J. M., Gluckman, T. J., Stone, N. J., Blumenthal, R. S., & McEvoy, J. W. (2019) · The American Journal of Medicine · doi:10.1016/j.amjmed.2019.01.031 · Cited by 14
Rana, J. S., Liu, J. Y., Moffet, H. H., Sanchez, R. J., Khan, I., & Karter, A. J. (2019) · The American Journal of Medicine · doi:10.1016/j.amjmed.2019.07.003 · Cited by 16
Management of Hyperlipidemia After Stroke
Brooks, D. C., & Schindler, J. (2019) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-019-0774-8 · Cited by 13
Colivicchi, F., Gulizia, M. M., Arca, M., Temporelli, P. L., Gonzini, L., Venturelli, V., Morici, N., Indolfi, C., Gabrielli, D., & Luca, L. D. (2020) · Cardiovascular Therapeutics · doi:10.1155/2020/3856242 · Cited by 15
“Furthermore, two large outcomes trials [13, 14] have consistently demonstrated that both evolocumab and alirocumab are effective in reducing by 15% (p < 0.”
BackgroundAllahyari, A., Jernberg, T., Lautsch, D., Lundman, P., Hagström, E., Schubert, J. R., Boggs, R. L., Salomonsson, S., & Ueda, P. (2020) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcaa016 · Cited by 15
Prospective Evaluation of Malignancy in 17,708 Patients Randomized to Ezetimibe Versus Placebo
Giugliano, R. P., Gencer, B., Wiviott, S. D., Park, J., Fuchs, C. S., Goessling, W., Musliner, T. A., Tershakovec, A. M., Blazing, M. A., Califf, R. M., et al. (2020) · JACC CardioOncology · doi:10.1016/j.jaccao.2020.07.008 · Cited by 15
Ingueneau, C., Hollstein, T., Grenkowitz, T., Ruidavets, J., Kassner, U., Duparc, T., Combes, G., Perret, B., Genoux, A., Schumann, F., et al. (2020) · Vascular Pharmacology · doi:10.1016/j.vph.2020.106804 · Cited by 18
Proprotein convertase subtilisin/kexin type 9 inhibition as the next statin?
Rakipovski, G., Hovingh, G. K., & Nyberg, M. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000718 · Cited by 15
“The fact that inclisiran reduces circulating PCSK9 levels by 80% where treatment with mAb’s reduce free circulating PCSK9 by more than 90% [9,10], may potentially result in up to an additional 20% decrease in LDL-C levels with mAb’s as compared with the siRNA approach.”
BackgroundZambon, A., Silva, A. M. E., & Farnier, M. (2020) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaa123 · Cited by 14
Scicali, R., Russo, G. I., Mauro, M. D., Manuele, F., Marco, G. D., Pino, A. D., Ferrara, V., Rabuazzo, A. M., Piro, S., Morgia, G., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9113597 · Cited by 14
“The clinical efficacy of PCSK9-i was shown in previous studies [19,20]; in particular, the reduction of LDL-C and ASCVD by PCSK9-i was '50–60% and 15%, respectively.”
MethodYu, R., Hou, R., Wang, T., Li, T., Han, H., & An, J. (2021) · Pakistan Journal of Medical Sciences · doi:10.12669/pjms.37.3.3469 · Cited by 17
Pleiotropy of PCSK9: Functions in Extrahepatic Tissues
Şener, Y. Z., & Tokgözoğlu, L. (2023) · Current Cardiology Reports · doi:10.1007/s11886-023-01918-2 · Cited by 13
Chung, C., Kao, Y., Chen, Y., Lin, Y., Higa, S., Hsu, K., & Chen, Y.-J. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051921 · Cited by 16
“Alirocumab, a novel PCSK9 monoclonal antibody, can decrease cardiac events and mortality in patients with MI [8].”
Girolamo, F. G. D., Pellin, L., Roni, C., Biolo, G., Sinagra, G., & Fabris, E. (2025) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2025.106442 · Cited by 16
Forzano, I., Florimonte, D., Narciso, V., Canonico, M. E., Castiello, D. S., Manzi, L., Cristiano, S., Spinelli, A. M., Vallone, D. M., D’Alconzo, D., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14238334 · Cited by 17
“In this trial, 18,924 participants were enrolled, with the findings demonstrating that the risk of recurrent ischemic CV was lower in the alirocumab group than in the placebo group (HR, 0.85; 95% CI, 0.78 to 0.93; p < 0.001) [36].”
InfluentialIhuoma, J., Milan, M., Negri, S., Troyano‐Rodriguez, E., Rudraboina, R., Kosmider, A., Awasthi, S., Csiszar, A., Ungvari, Z. I., Yabluchanskiy, A., et al. (2026) · Redox Biology · doi:10.1016/j.redox.2026.104118 · Cited by 18
Treatment Inertia in Patients With Familial Hypercholesterolemia
Langer, A., Mancini, G. B. J., Tan, M., Goodman, S. G., Ahooja, V., Grégoire, J. C., Lin, P., Stone, J. A., & Leiter, L. A. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.020126 · Cited by 12
Self-citationLiang, J., Li, W., Liu, H., Li, X., Yuan, C., Zou, W., & Qu, L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.857092 · Cited by 14
Inter-Individual Variability in Lipid Response: A Narrative Review
Patnaik, S., Pollevick, M. E., Lara-Breitinger, K. M., & Stone, N. J. (2022) · The American Journal of Medicine · doi:10.1016/j.amjmed.2022.06.018 · Cited by 14
Antihyperlipidemic Treatment Options in Statin Resistance and Intolerance
Danilov, A., Frishman, W. H., & Aronow, W. S. (2022) · Cardiology in Review · doi:10.1097/crd.0000000000000498 · Cited by 12
Long-term Management of Patients with Myocardial Infarction: An Updated Review
Chen, R., Zhao, H., & Yan, H. (2022) · Cardiology Discovery · doi:10.1097/cd9.0000000000000073 · Cited by 13
“[38–42] Therefore, it is possible to use more intensive lipid-lowering treatments to achieve lower LDL-C goals [Table 2].[37,38,41,42] In contrast, a considerable number of patients fail to reach the pre-specified targets despite the use of current optimal medications, while others still suffer from adverse events due…”
BackgroundMethodBenefits of Bempedoic Acid — Clearer Now
Alexander, J. H. (2023) · New England Journal of Medicine · doi:10.1056/nejme2301490 · Cited by 12
Gupta, R. M., Schnitzler, G. R., Fang, S., Lee-Kim, V. S., & Barry, A. E. (2023) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.123.318328 · Cited by 14
Mohammadi, K. A., Brackin, T., Schwartz, G. G., Steg, P. G., Szarek, M. J., Manvelian, G. Z., Pordy, R. C., Fazio, S., & Geba, G. P. (2023) · Cancer Medicine · doi:10.1002/cam4.6310 · Cited by 11
Self-citationDutta, S., Shah, R., Singhal, S., Singh, S., Piparva, K. G., & Katoch, C. D. S. (2023) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2023.2293201 · Cited by 13
Bentzel, S., Ljungman, C. E. A., Hjerpe, P., Schiöler, L., Manhem, K., Boström, K. B., Kahan, T., & Mourtzinis, G. (2023) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwad389 · Cited by 14
PCSK9 genetic variants and risk of vascular and non-vascular diseases in Chinese and UK populations
Holmes, M. V., Kartsonaki, C., Boxall, R., Lin, K., Reeve, N. F., Yu, C., Lv, J., Bennett, D., Hill, M., Yang, L., et al. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae009 · Cited by 14
“3,4 Compared with statins, PCSK9 inhibitors (e.g. evolocumab and incli-siran) are relatively new, with much less comprehensive long-term data concerning their benefits and potential side-effects.”
Influential
Metadata
- Authors
- Schwartz, G. G., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., Jukema, J. W., Lecorps, G., Mahaffey, K. W., Moryusef, A., Pordy, R., Quintero, K., Roe, M. T., Sasiela, W. J., Tamby, J.-F., Tricoci, P., White, H. D., & Zeiher, A. M.
- Affiliations
- Inserm (FR)
- From the Division of Cardiology, University of Colorado School of Medicine, Aurora (G.G.S.); Assistance Publique–Hôpitaux de Paris, Hôpital Bichat, Paris Diderot University, Sorbonne Paris Cité, FACT (French Alliance for Cardiovascular Trials), and INSERM Unité 1148 (P.G.S.), and Sanofi (C.H., G.L.) — all in Paris; the National Heart and Lung Institute, Imperial College, Royal Brompton Hospital, London (P.G.S.); the State University of New York Downstate School of Public Health, Brooklyn (M.S.), and...
- State University of New York (US)
- Brigham and Women's Hospital (US)
- St. Michael's Hospital (CA)
- Goethe University Frankfurt (DE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-11-29
- Volume
- 379
- Issue
- 22
- Pages
- 2097-2107
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2899997727
- Semantic Scholar
- 3bd18f4d47c498a70a737151f3b2a9a1a09050bd
- Cited by
- 3,634
- References
- 22
- Citations by year
- 2026: 452 · 2025: 403 · 2024: 450 · 2023: 446 · 2022: 471 · 2021: 473 · 2020: 481 · 2019: 414 · 2018: 31
- FWCI
- 363.89
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- SZTE Publicatio Repozitórium (University of Szeged) (acceptedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- Leiden Repository (Leiden University) (submittedVersion)
- Lanzhou University Institutional Repository (submittedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- HAL (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Institutional Repositories DataBase (IRDB) (submittedVersion, cc-by-nc-nd)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Lirias (submittedVersion)
- Dspace Repository (Marmara Üniversitesi) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Griffith Research Online (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Sanofi
- Regeneron Pharmaceuticals
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Keywords
- alirocumab, PCSK9 inhibitors, acute coronary syndrome, cardiovascular outcomes, LDL cholesterol lowering, high-intensity statin therapy, LDL cholesterol targets, cardiovascular mortality, myocardial infarction, ischemic stroke, unstable angina, apolipoprotein B, non-HDL cholesterol, secondary prevention, cardiovascular risk reduction, LDL-C lowering therapy
- MeSH terms
- Proprotein Convertase 9, PCSK9 Inhibitors, Adult, Aged, Antibodies, Monoclonal, Anticholesteremic Agents, Cardiovascular Diseases, Double-Blind Method, Female, Follow-Up Studies, Humans, Hypercholesterolemia, Cholesterol, LDL, Male, Middle Aged, Acute Coronary Syndrome, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-08, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-08 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

